136 173

Cited 1 times in

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease

Authors
 Jihye Park  ;  Jae Hee Cheon 
Citation
 GUT AND LIVER, Vol.12(6) : 623-632, 2018 
Journal Title
 GUT AND LIVER 
ISSN
 1976-2283 
Issue Date
2018
Keywords
Adalimumab ; Anti-tumor necrosis factor alpha ; Behcet syndrome ; Infliximab ; Intestinal Behcet’s disease
Abstract
Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor-α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet's disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor-α for the treatment of intestinal Behçet's disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet's disease. This review also discusses safety issues associated with anti-tumor necrosis factor-α, including vulnerability to infections and malignancy.
Files in This Item:
T201805583.pdf Download
DOI
10.5009/gnl17462
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Ji Hye(박지혜)
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/167572
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links